

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 18, 2018

PARATEK PHARMACEUTICALS, INC.

(Exact name of Registrant as specified in its charter)

Delaware
(State or other jurisdiction
of incorporation)

001-36066
(Commission
File Number)

33-0960223
(I.R.S. Employer
Identification No.)

75 Park Plaza
Boston, MA
(Address of principal executive offices)

02116
(Zip Code)

(617) 807-6600
(Registrant's telephone number, including area code)

Not applicable
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 2.02 Results of Operations and Financial Condition.

Paratek Pharmaceuticals, Inc. (the "Company") is currently in the process of finalizing its financial results for the three months ended March 31, 2018. Based on information currently available, management estimates the Company's (i) cash, cash equivalents and marketable securities and (ii) gross current and long-term debt obligations as of March 31, 2018 to be approximately \$184.3 million and \$60.0 million, respectively. The Company also estimates that as of March 31, 2018, (a) it had outstanding approximately 31,443,149 shares of its common stock and (b) approximately 5,982,275 shares of its common stock subject to outstanding stock options, restricted stock units and warrants. Actual results and financial data as of March 31, 2018 may differ from the above estimates due to the completion of the Company's closing procedures with respect to the three months ended March 31, 2018, final adjustments and other developments that may arise between now and the time the financial results for the three months ended March 31, 2018 are finalized.

The information furnished under this Item 2.02 shall not be considered "filed" under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), nor shall it be incorporated by reference into any future filing under the Securities Act of 1933, as amended, or under the Exchange Act unless the Company expressly sets forth in such future filing that such information is to be considered "filed" or incorporated by reference therein.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PARATEK PHARMACEUTICALS, INC.

Date: April 18, 2018

By: /s/ Douglas W. Pagán
Douglas W. Pagán
Chief Financial Officer